Genetic Technologies (ASX:GTG) has published a research paper in the peer-reviewed journal Cancer Prevention Research that demonstrates the utility of its geneType Breast Cancer Risk Assessment Test.
The study compared geneType to a gold-standard model and found that geneType not only put more women into an increased risk category, but also demonstrated women in this category developed breast cancer at a higher incidence.
The study is the third paper accepted for publication in the last six months that highlights the utility of geneType.
Genetic Technologies says it's hoping the research will help them gain traction with US Payers to initiate a pilot study.